乳腺癌术后辅助化疗时机的选择  

The timing of adjuvant chemotherapy for breast cancer:A review

作　　者：杜小双 常莉[2] 王丽[2] 侯宇[2] 李兰[2] 龙清[2] 柏晗[2] 夏耀雄[2] 陆叶[1] 李文辉[2] 

机构地区：[1]昆明医科大学,云南昆明650500 [2]昆明医科大学第三附属医院,云南昆明650100

出　　处：《现代肿瘤医学》2017年第11期1837-1840,共4页Journal of Modern Oncology

摘　　要：乳腺癌术后辅助化疗的时机选择问题,相关研究层出不穷并仍在继续,但目前为止尚无定论。术后辅助化疗的时机对患者的生存有影响,早期乳腺癌患者辅助化疗时机超过12周与患者较差的生存相关,早期快速增殖型乳腺癌辅助化疗时机在7周内将使患者生存获益。III期、三阴性以及HER-2阳性且接受曲妥珠单克隆抗体治疗等高危乳腺癌患者,术后辅助化疗时机超过61天对生存结局造成不利影响。对于术后的辅助化疗总体来说,在患者状况允许的前提下,尽快制定化疗方案,尽早化疗,避免延迟。The relevant studies focused on the timing of adjuvant chemotherapy after breast cancer surgery are emer-ging and still continue. However,there is still no consensus. Postoperative adjuvant chemotherapy time afected on the patients survival and early breast cancer patients treated w ith adjuvant chemotherapy time more than 12 weeks related to poor patient survival. The timin g o f adjuvant chemotherapy fo r early stage rapid prol iferative breast cancer will ben-efit patients in 7 weeks. Patients with stage ⅢB C , TNBC ,and trastuzumab - treated HER2 - positive tumors experi-enced worse outcomes when chemotherapy was delayed 61 days. For postoperative adjuvant chemotherapy in general, under the premise of the patient condition , we should develop chemotherapy regimen , to avoid delay as soon as ossible.

关 键 词：乳腺癌 辅助化疗 化疗时机 

分 类 号：R737.9[医药卫生—肿瘤]